【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於有骨折風險之老年人。 【藥品訊息】 易復樂內服液劑 仿單

Generalized anxiety disorder, major depressive disorder

Escitalopram oxalate, a selective serotonin reuptake inhibitor (SSRI) and S-enantiomer of racemic citalopram, enhances serotonergic activity in the central nervous system (CNS) as a result of its inhibition of serotonin (5-HT) reuptake in CNS neurons.

Absorption: Escitalopram oxalate, Oral: time to peak concentration, about 5 h.
Distribution: Protein binding: approximately 56%.
Metabolism: Escitalopram oxalate-Hepatic; P450 CYP3A4 and CYP2C19; N-demethylation.
Excretion: Renal: 10% as S-DCT, 8% unchanged.
Elimination Half Life: Escitalopram oxalate: 27 h to 32 h (mean).

Increased risk of serotonin syndrome with concomitant use with an MAOI, including linezolid or IV methylene blue, or use of escitalopram within 14 days of discontinuing an MAOI used to treat psychiatric disorders, or use of an MAOI used to treat psychiatric disorders within 14 days of discontinuing escitalopram.
Hypersensitivity to citalopram, escitalopram, or any other component of the product.

C (FDA)

Infant risk has been demonstrated.

Common:
Dermatologic: Diaphoresis
Gastrointestinal: Abdominal pain, Constipation, Diarrhea, Indigestion, Nausea, Vomiting, Xerostomia
Neurologic: Dizziness, Headache, Insomnia, Somnolence
Reproductive: Disorder of ejaculation, Erectile dysfunction, Orgasm incapacity, Reduced libido
Other: Fatigue, Withdrawal sign or symptom
Serious:
Hematologic: Hemorrhage, Abnormal
Psychiatric: Depression, worsening, Suicidal thoughts, Suicide
Other: Serotonin syndrome.

Generalized anxiety disorder:
Initial, 10 mg/day orally as a single dose in the morning or evening; may increase to 20 mg/day after a minimum of 1 week.
Major depressive disorder:
Initial, 10 mg/day orally as a single dose in the morning or evening; may increase to 20 mg/day after a minimum of 1 week.

Major depressive disorder (12 years or older) Initial, 10 mg/day orally as a single dose in the morning or evening; may increase to 20 mg/day after a minimum of 3 weeks.

Renal impairment, mild to moderate: No adjustment necessary.

Hepatic impairment: 10 mg/day orally.